Cargando…

Thrombosis with thrombocytopenia after AZD1222 (ChAdOx1 nCov-19) vaccination: Case characteristics and associations

BACKGROUND: Post-marketing surveillance for COVID-19 vaccines during the pandemic identified an extremely rare thrombosis with thrombocytopenia syndrome (TTS) reported post-vaccination, requiring further characterisation to improve diagnosis and management. METHODS: We searched the AstraZeneca Globa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Laffan, Michael A, Rees, Sue, Yadavalli, Madhavi, Ferstenberg, Lisa Beth, Kumar Shankar, Nirmal, Medin, Jennie, Foskett, Nadia, Arnold, Matthew, Gomes da Silva, Hugo, Bhuyan, Prakash, Nord, Magnus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Authors. Published by Elsevier Ltd. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9388294/ https://www.ncbi.nlm.nih.gov/pubmed/35989136 http://dx.doi.org/10.1016/j.vaccine.2022.08.007

Ejemplares similares

Geographical distribution of TTS cases following AZD1222 (ChAdOx1 nCoV-19) vaccination
por: Soboleva, Karina, et al.
Publicado: (2022)

Very rare thrombosis with thrombocytopenia after second AZD1222 dose: a global safety database analysis
por: Bhuyan, Prakash, et al.
Publicado: (2021)

Developmental and reproductive safety of AZD1222 (ChAdOx1 nCoV-19) in mice
por: Stebbings, Richard, et al.
Publicado: (2021)

AZD1222 (ChAdOx1 nCov-19): A Single-Dose biodistribution study in mice
por: Stebbings, Richard, et al.
Publicado: (2022)

Serum levels of anti-PF4 IgG after AZD1222 (ChAdOx1 nCoV-19) vaccination
por: Cohen, Taylor S., et al.
Publicado: (2022)

Fertility rates and birth outcomes after ChAdOx1 nCoV-19 (AZD1222) vaccination
por: Hillson, Kushalinii, et al.
Publicado: (2021)

An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females
por: Marchevsky, Natalie Gabrielle, et al.
Publicado: (2022)

Antibody Response to ChAdOx1 nCoV-19 (AZD1222) Vaccine in Kidney Transplant Recipients
por: Bhadauria, Dharmendra S., et al.
Publicado: (2022)

Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine
por: Falsey, Ann R., et al.
Publicado: (2021)

Alopecia universalis with unusual histopathologic features after vaccination with ChAdOx1 nCoV-19 (AZD1222)
por: Ho, Jonathan D., et al.
Publicado: (2022)

Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months
por: Sobieszczyk, Magdalena E., et al.
Publicado: (2022)

Vogt-Koyanagi-Harada Syndrome following COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccine
por: Saraceno, Janaína Jamile Ferreira, et al.
Publicado: (2021)

Antibody levels in people with diabetes after one dose of the ChAdOx1 nCoV-19 (AZD1222) vaccine
por: Rangsrisaeneepitak, Vimonsri, et al.
Publicado: (2022)

Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine
por: Benkeser, David, et al.
Publicado: (2023)

ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants
por: van Doremalen, Neeltje, et al.
Publicado: (2022)

Acute herpes zoster radiculopathy mimicking cervical radiculopathy after ChAdOx1 nCoV-19/AZD1222 vaccination
por: Dermawan, Andrew, et al.
Publicado: (2022)

Livedo reticularis following administration of ChAdOx1 nCoV-19 vaccine (AZD1222): a report of two cases
por: Kim, Joong Ho, et al.
Publicado: (2022)

Safety and Reactogenicity of the ChAdOx1 (AZD1222) COVID-19 Vaccine in Saudi Arabia
por: Al Bahrani, Salma, et al.
Publicado: (2021)

Genomic Analysis of AZD1222 (ChAdOx1) Vaccine Breakthrough Infections in the City of Mumbai
por: Shetty, Arusha, et al.
Publicado: (2022)

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination
por: Greinacher, Andreas, et al.
Publicado: (2021)

Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine
por: Watanabe, Yasunori, et al.
Publicado: (2021)

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil
por: Clemens, Sue Ann Costa, et al.
Publicado: (2021)

Immunogenicity after Second ChAdOx1 nCoV-19 (AZD1222) Vaccination According to the Individual Reactogenicity, Health Status and Lifestyle
por: Choi, Hyunji, et al.
Publicado: (2021)

ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets
por: Marsh, Glenn A., et al.
Publicado: (2021)

Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccine
por: Watanabe, Yasunori, et al.
Publicado: (2021)

S-11-03 Accelerated timelines for non-clinical studies to support COVID-19 vaccine (AZD1222, ChAdOx1-nCov19)
por: Stebbings, R.
Publicado: (2022)

ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19
por: Kaplonek, Paulina, et al.
Publicado: (2023)

Rapid progressive vaccine-induced immune thrombotic thrombocytopenia with cerebral venous thrombosis after ChAdOx1 nCoV-19 (AZD1222) vaccination: A case report
por: Jiang, Shin-Kuang, et al.
Publicado: (2022)

High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events
por: Terpos, Evangelos, et al.
Publicado: (2021)

Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
por: Schultz, Nina H., et al.
Publicado: (2021)

Safety and incidence of COVID-19 following ChAdOx1(AZD1222) COVID-19 vaccination in Botswana
por: Shava, Emily, et al.
Publicado: (2023)

Immunogenicity evaluation of ChAdox1 nCov-19 (AZD1222) vaccine in solid cancer patients in Chulabhorn Hospital
por: Limpawittayakul, Piyarat, et al.
Publicado: (2022)

The clinicopathological features of thrombosis with thrombocytopenia syndrome following ChAdOx1-S (AZD1222) vaccination and case outcomes in Australia: a population-based study
por: Tran, Huyen A., et al.
Publicado: (2023)

SARS-CoV-2 Spike Protein Expression In Vitro and Hematologic Effects in Mice Vaccinated With AZD1222 (ChAdOx1 nCoV-19)
por: Stebbings, Richard, et al.
Publicado: (2022)

REATOGENICIDADE COM MEIA DOSE DA VACINA CHADOX1 NCOV-19 (AZD1222)
por: Gouvea, Maria da Penha Gomes, et al.
Publicado: (2022)

The Clinicalpathological Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT) Following ChAdOx1 (AstraZeneca AZD1222) Vaccination and Case Outcomes in Australia
por: Tran, Huyen, et al.
Publicado: (2022)

Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces shedding of SARS-CoV-2 D614G in rhesus macaques
por: van Doremalen, Neeltje, et al.
Publicado: (2021)

Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials
por: Voysey, Merryn, et al.
Publicado: (2023)

Thrombosis with Thrombocytopenia Syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination – A risk–benefit analysis for people < 60 years in Australia
por: MacIntyre, Chandini Raina, et al.
Publicado: (2021)

Waning of Anti-spike Antibodies in AZD1222 (ChAdOx1) Vaccinated Healthcare Providers: A Prospective Longitudinal Study
por: Mishra, Sanjeeb K, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_17e6kp1ksabcprrv0rql4bcpm0